Federica Catalanotti

1.5k total citations
15 papers, 1.2k citations indexed

About

Federica Catalanotti is a scholar working on Molecular Biology, Ophthalmology and Oncology. According to data from OpenAlex, Federica Catalanotti has authored 15 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Ophthalmology and 3 papers in Oncology. Recurrent topics in Federica Catalanotti's work include Melanoma and MAPK Pathways (7 papers), Ocular Oncology and Treatments (6 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Federica Catalanotti is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), Ocular Oncology and Treatments (6 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Federica Catalanotti collaborates with scholars based in United States, Austria and Italy. Federica Catalanotti's co-authors include Catia Traversari, Barbara Valentinis, Marco E. Bianchi, Susanne Müller, M. Giazzon, Matteo Iannacone, Ingrid E. Dumitriu, Annalisa Capobianco, Patrizia Rovere‐Querini and Angelo A. Manfredi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Federica Catalanotti

15 papers receiving 1.2k citations

Peers

Countries citing papers authored by Federica Catalanotti

Since Specialization

Citations

This map shows the geographic impact of Federica Catalanotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federica Catalanotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federica Catalanotti more than expected).

Fields of papers citing papers by Federica Catalanotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federica Catalanotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federica Catalanotti. The network helps show where Federica Catalanotti may publish in the future.

Co-authorship network of co-authors of Federica Catalanotti

This figure shows the co-authorship network connecting the top 25 collaborators of Federica Catalanotti. A scholar is included among the top collaborators of Federica Catalanotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federica Catalanotti. Federica Catalanotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds 2018 ·British Journal of Ophthalmology ·David H. Abramson, Xunda Ji, Jasmine H. Francis, Federica Catalanotti, Scott E. Brodie, Larissa A. Habib	41
2	Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma 2018 ·British Journal of Ophthalmology ·Jasmine H. Francis, Federica Catalanotti, Jonathan Landa, Christopher A. Barker, Alexander N. Shoushtari, David H. Abramson	7
3	GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas 2018 ·Ophthalmology ·Jasmine H. Francis, Tatyana Milman, Hans E. Grossniklaus, Daniel M. Albert, Robert Folberg, (unknown), Sarah E. Coupland, Federica Catalanotti, (unknown), Cyriac Kandoth, Klaus J. Busam, David H. Abramson	22
4	Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery 2018 ·PLoS ONE ·Sruti S. Akella, Jasmine H. Francis, Andrea Knežević, Irina Ostrovnaya, Y. Pierre Gobin, Danielle Novetsky Friedman, (unknown), (unknown), Federica Catalanotti, David H. Abramson	4
5	Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma 2018 ·Ophthalmic Genetics ·David H. Abramson, Federica Catalanotti, Scott E. Brodie, Michael Kellick, Jasmine H. Francis	10
6	Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy 2017 ·Ophthalmology ·Jasmine H. Francis, Larissa A. Habib, David H. Abramson, Lawrence A. Yannuzzi, M. Heinemann, Mrinal M. Gounder, Rachel N. Grisham, Michael A. Postow, Alexander N. Shoushtari, Ping Chi, Neil H. Segal, Rona Yaeger, Alan L. Ho, Paul B. Chapman, Federica Catalanotti	94
7	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma 2017 ·JCO Precision Oncology ·Federica Catalanotti, Donavan T. Cheng, Alexander N. Shoushtari, Douglas B. Johnson, Katherine S. Panageas, Parisa Momtaz, Catherine Higham, Helen Won, James J. Harding, Taha Merghoub, Neal Rosen, Jeffrey A. Sosman, Michael F. Berger, Paul B. Chapman, David B. Solit	49
8	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases 2015 ·The Oncologist ·James J. Harding, Federica Catalanotti, Rodrigo Ramella Munhoz, Donavan T. Cheng, Amin Yaqubie, Nicole Kelly, Gregory C McDermott, (unknown), Taha Merghoub, Mario E. Lacouture, Richard D. Carvajal, Katherine S. Panageas, Michael F. Berger, Neal Rosen, David B. Solit, Paul B. Chapman	50
9	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma 2013 ·Clinical Cancer Research ·Federica Catalanotti, David B. Solit, Melissa Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunç Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman	112
10	MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance 2013 ·Molecular Cell ·(unknown), Veronika Jesenberger, Federica Catalanotti, Christian Baumgärtner, Gloria Reyes, Manuela Baccarini	79
11	Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets). 2013 ·Journal of Clinical Oncology ·James J. Harding, Federica Catalanotti, Amin Yaqubie, (unknown), (unknown), Taha Merghoub, Richard D. Carvajal, Sandra P. D’Angelo, Mark A. Dickson, Gary K. Schwartz, Jedd D. Wolchok, Michael F. Berger, David B. Solit, Paul B. Chapman	4
12	A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal 2009 ·Nature Structural & Molecular Biology ·Federica Catalanotti, Gloria Reyes, Veronika Jesenberger, Gergana Galabova‐Kovacs, Ricardo De Matos Simoes, Oliviero Carugo, Manuela Baccarini	131
13	Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development 2008 ·The Journal of Cell Biology ·Gergana Galabova‐Kovacs, Federica Catalanotti, (unknown), Gloria Reyes, Jürgen Zezula, Ruth Herbst, Alcino J. Silva, Ingrid Walter, Manuela Baccarini	70
14	Direct Effects of Polymyxin B on Human Dendritic Cells Maturation 2005 ·Journal of Biological Chemistry ·Barbara Valentinis, (unknown), Dan Zhou, Arcadi Cipponi, Federica Catalanotti, Vincenzo Russo, Catia Traversari	38
15	HMGB1 is an endogenous immune adjuvant released by necrotic cells 2004 ·EMBO Reports ·Patrizia Rovere‐Querini, Annalisa Capobianco, Paola Scaffidi, Barbara Valentinis, Federica Catalanotti, M. Giazzon, Ingrid E. Dumitriu, Susanne Müller, Matteo Iannacone, Catia Traversari, Marco E. Bianchi, Angelo A. Manfredi	499

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact